Ivonescimab for the Treatment of Thymic Cancer

Summary

This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2025-07-15

Primary completion

2027-06-17

Completion

2028-06-17

Drugs

Indications